Lanean...
97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
BACKGROUND: Baloxavir marboxil (BXM), a cap-dependent endonuclease inhibitor, has been recently approved in the United States for the treatment of influenza infections. It is superior to oseltamivir for reducing the time of viral shedding but is reported to have a low barrier of resistance. We sough...
Gorde:
| Argitaratua izan da: | Open Forum Infect Dis |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6808909/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.021 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|